Eli Lilly and Company announced results from a real-world study of adults over 55 with overweight or obesity, which found that staying on Zepbound (tirzepatide) for weight management… read more.
Eli Lilly and Company announced that the FDA approved Mounjaro (tirzepatide), a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of major adverse cardiovascular (CV)… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) authorised orforglipron (Foundayo), making the UK the first country in Europe to approve this GLP-1 tablet for weight management and type 2 diabetes. Alongside a reduced-calorie diet and increased… read more.
Eli Lilly and Company announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jaypirca (pirtobrutinib), a… read more.
Eli Lilly and Company, the maker of Zepbound (tirzepatide), announced results demonstrating that women with obesity or overweight who took the highest dose of Foundayo experienced significant weight… read more.
Eli Lilly and Company announced positive topline results from the Phase III LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant therapy versus placebo. The study met its primary… read more.
New long-term data from Eli Lilly and Company showed Omvoh (mirikizumab-mrkz) delivered durable efficacy through three years in adults with moderately to severely active Crohn’s disease. These data… read more.
Eli Lilly and Company announced that Foundayo (orforglipron) is now available to adults with obesity or overweight with weight-related medical problems following the FDA approval on April 1,… read more.
Eli Lilly and Company announced the FDA approved Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems. When used alongside a reduced-calorie diet and increased… read more.
Eli Lilly and Company announced that access to self-pay pricing on the new Zepbound (tirzepatide) KwikPen for single-patient use will be available at LillyDirect and major pharmacies nationwide,… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has approved imlunestrant tosylate (Inluriyo), a new treatment for adult patients with a certain type of breast… read more.
Eli Lilly and Company announced the FDA approved a label expansion for Zepbound (tirzepatide) to include the four-dose single-patient use KwikPen that delivers a full month of treatment… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
